Elizabeth Holmes, the young CEO of blood-testing start-up Theranos, has had a standing invitation for the past few years to present at the annual summit for laboratory medicine, the conference of the American Association for Clinical Chemistry.
It was only after serious questions about her technology — and a ban on her operating clinical labs — arose this year that she finally accepted.
“We want to know what it is that she’s so secretive about, how she’s doing what she says she’s doing,” said Patricia Jones, president of the AACC and professor of pathology at the University of Texas Southwestern Medical Center in Dallas.
